Asher Bio Patents

Patent portfolio assigned to Asher Bio (verified via public assignee records). Asher Biotherapeutics (South San Francisco), cis-targeted immunotherapy. Patent WO2022245500A1 (IL-21 polypeptides and targeted constructs) lists Asher Biotherapeutics Inc as assignee (Google Patents). Merck named as clinical-trial collaborator (AB248 + KEYTRUDA) on company press page. No reliable direct-competitor source beyond aggregators, so competitors left empty.